Axogen AXGN
Axogen FY 2022: revenue $138.6M, up 9%; diluted EPS −$0.69
- Form
- 10-K/A
- Filed
- Period
- Importance
- Routine
- Accession
- 0000805928-23-000044
- Document
- 10-K/A
Key figures from this report
These are the numbers Axogen reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$138.6M+9% from $127.4M in FY 202110-K income statement, on EDGAR
- Net income−$28.9MAgainst −$27.0M in FY 202110-K income statement, on EDGAR
- Diluted EPS−$0.69Against −$0.65 in FY 202110-K income statement, on EDGAR
- Cash and cash equivalents$15.3M−53% from $32.8M in FY 2021Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$16.1MAgainst −$13.4M in FY 202110-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 3845 and related industry codes: the same peer list as the financial tables.
- Angiodynamics ANGO public float $436M, Nov 30, 2025
- Orthofix Medical OFIX public float $440M, Jun 30, 2025
- Delcath Systems DCTH public float $420M, Jun 30, 2025
- Ceribell CBLL public float $417M, Jun 30, 2025
- Pulse Biosciences PLSE public float $394M, Jun 30, 2025
